Johnson & Johnson acquires Firefly Bio for $1 billion

Johnson & Johnson acquires Firefly Bio for $1 billion Quartz · Jeff Schear / Getty Images Colleen Cabili Mon, June 8, 2026 at 3:33 PM GMT+2 1 min read JNJ Johnson & Johnson agreed to acquire Firefly Bio, Inc. for $1 billion in cash, the company said Monday, expanding its cancer drug pipeline with a platform designed to treat tumors that have resisted conventional therapies. At the heart of the deal is Firefly's Firelink platform, which is designed to slip protein-degrading drugs inside cancer cells by hitching them to antibodies — a strategy intended to spare healthy tissue from the collateral damage typical of existing treatments, Reuters reported.

The platform targets tumors driven by a mutation in a gene known as KRAS, the company said. "KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years," said John Reed, executive vice president of innovative medicine, research and development at Johnson & Johnson, in a statement. "We believe the proprietary Firelink platform will overcome the limitations of current treatments and diversify our pipeline with preclinical candidates for treating multiple types of solid tumors.

" Pending regulatory approvals and other standard closing conditions, J&J expects the deal to be finalized before the end of 2026. The acquisition adds to Johnson & Johnson's oncology business at a moment of broad momentum across its Innovative Medicine segment. The company reported first-quarter revenue of $24.

1 billion , up about 10% from a year earlier, and raised its full-year 2026 sales outlook to a range of $100. 3 billion to $101. 3 billion.

Growth in the quarter was driven in part by oncology therapies including Darzalex, which brought in $4. 0 billion. J&J also committed more than $1 billion during the quarter to build a cell therapy manufacturing facility in Pennsylvania.